- Home
- PLBL vs ACLX Comparison
PLBL vs ACLX Comparison
Compare PLBL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBL | ACLX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PLBL | ACLX |
|---|---|---|
| Price | $9.30 | $68.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $113.75 |
| AVG Volume (30 Days) | 11.0K | ★ 868.4K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $30,226,939.00 | ★ $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $309.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.62 | N/A |
| 52 Week Low | $5.60 | $47.86 |
| 52 Week High | $14.31 | $94.07 |
Technical Indicators
Market Signals| Indicator | PLBL | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 50.12 |
| Support Level | $8.32 | $66.12 |
| Resistance Level | $9.30 | $70.34 |
| Average True Range (ATR) | 0.68 | 2.64 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 39.25 | 46.39 |
Price Performance
Historical ComparisonAbout PLBL Polibeli Group Ltd Class A Ordinary Shares
Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.